Contact this trialFirst, we need to learn more about you.
Androgen Synthesis Inhibitor
ARN-509 +/− Abiraterone for Prostate Cancer
Recruiting1 awardPhase 2
New Haven, Connecticut
This trial is testing a new combo of drugs for high-risk prostate cancer patients undergoing surgery. The drugs lower androgen levels, which can cause prostate cancer growth. Prednisone may either kill the tumor cells or stop them from dividing.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service